Pembrolizumab Shows Promise for Unmet Need in NMIBC
Published: Wednesday, May 22, 2019
Arjun V. Balar, MD
Early data indicate that pembrolizumab (Keytruda) is a feasible option for patients with high-risk nonmuscle–invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette-Guérin (BCG), explained Arjun V. Balar, MD.
... to read the full story